Asher Biotherapeutics, Inc.

This is the first human study of a new cancer drug called AB248, testing it alone or combined with an existing immunotherapy (pembrolizumab). The trial aims to find safe doses and see early signs of effectiveness in adults with advanced solid tumors that have spread or cannot be …